Menu
Recruiting NCT07315997

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

Observational Rheumatoid Arthritis (RA Atherosclerotic Cardiovascular Disease (ASCVD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: high sensitivity cardiac troponin.
Who it may be relevant to
Registry conditions: Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD). Basic parameters: 35 years — 79 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying individuals at risk before they develop symptoms of heart disease and start preventative treatment earlier.

Detailed description

The objective of this study is to test the utility of high sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (CAC) in risk stratifying patients with rheumatoid arthritis (RA) who may benefit from lipid lowering therapy. The population of interest are individuals who would not otherwise be recommended for therapy based on general population risk calculators for heart disease risk.

Interventions

  • Diagnostic test high sensitivity cardiac troponin
    Blood measurement of high sensitivity cardiac troponin

Primary outcome measures

  • coronary artery calcium score [Time frame: Cross-sectional, at baseline]

Eligibility criteria

Inclusion criteria

  • RA diagnosed by a rheumatologist
  • Age 40- 79
  • ≥1 ASCVD risk factor including prediabetes, hypertension, BMI >30, current or history of cigarette smoking

Exclusion criteria

  • Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor
  • Patients with diabetes mellitus
  • Pregnancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 3 centers
  • Massachusetts General Hospital: Rheumatology — Boston
  • Brigham and Womens Hospital — Boston
  • Brigham and Women's Faulkner Hospital — Boston

Identifiers

NCT: NCT07315997 · 2024P001981

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗